Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Holders of 5% or more of PLX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Protalix BioTherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G | 5.02%4.05M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
14 Schedule 13D and 13G filings on Protalix BioTherapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 29, 20263:19 PM ET | BlackRock, Inc. | 13G | 5.02%4.05M shares | New | Jun 30, 2026 | SEC |
| Mar 30, 20265:31 PM ET | MAK Capital Fund LPand 2 others | 13G/A | 4.50%3.62M shares | −1.30 ppfrom 5.80%Below 5% | Mar 24, 2026 | SEC |
| Mar 4, 20264:40 PM ET | MAK Capital Fund LPand 2 others | 13G | 5.80%4.65M shares | New | Feb 26, 2026 | SEC |
| Feb 14, 2022 | Highbridge Capital Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Highbridge Capital Management LLC | 13G/AOld format | – | – | – | SEC |
| Jan 31, 2022 | Nacht Marius | 13G/AOld format | – | – | – | SEC |
| Jul 30, 2021 | Burrage Capital Management LLC | 13G/AOld format | – | – | – | SEC |
| Jun 15, 2021 | Dexcel Pharma Technologies Ltd. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | UBS Oconnor LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Dexcel Pharma Technologies Ltd. | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Burrage Capital Management LLC | 13GOld format | – | New | – | SEC |
| Feb 9, 2021 | Highbridge Capital Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 8, 202111:51 AM ET | Citigroup Inc | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2021 | Nacht Marius | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Protalix BioTherapeutics, Inc. shares.
No Form 144 notices for Protalix BioTherapeutics, Inc. are on file.